Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus CORPHEDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus CORPHEDRA.
CLARINEX-D 12 HOUR vs CORPHEDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
CorphEdra is a synthetic glucocorticoid that binds to the glucocorticoid receptor (GR), leading to transcriptional regulation of anti-inflammatory and immunosuppressive genes. It also activates the mineralocorticoid receptor (MR) with lower affinity, contributing to electrolyte and fluid balance effects.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
10-20 mg orally every 8 hours as needed for nasal congestion.
None Documented
None Documented
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
8-12 hours (terminal); clinical context: requires dosing every 12 hours; reduced clearance in elderly and renal impairment
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine/Decongestant